TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01547091

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)
Description: -The UC-MSCs will be infused intravenously(single dose, 4x10\^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs)
Description: -Patients will be treated by conventional drugs (DMARDS) for alleviating disease.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: UC-MSC+DMARDS
Description: The UC-MSCs will be infused intravenously(single dose, 4x10\^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.Meanwhile,patients will be treated by conventionally drugs if the disease is still not alleviated.
Study: NCT03987906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom screening with Targeted Early Palliative Care (STEP)
Description: The experimental arm receives routine symptom screening at every outpatient visit; if symptoms are above a certain threshold, then a triggered email is sent to a triage nurse, who calls the patient to offer early referral to and follow-up by a symptom control and palliative care team.
Study: NCT01885910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 100mg
Description: Doxycycline 100mg by mouth once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aczone 5% gel
Description: Aczone 5% gel twice daily
Study: NCT01417364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone enanthate
Description: 100 mg. IM weekly throughout study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate
Description: 100 mg IM weekly for one month alternating with placebo injections for one month throughout the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injected IM weekly throughout study
Study: NCT02054884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm A: F16IL2 in combination with paclitaxel
Description: Intravenous (i.v.) 1 hour infusions of paclitaxel 90 mg/m\^2 followed, after 30 min pause, by 3 hour i.v. infusions of F16IL2 35 Mio IU on days 1, 8, 15 of each 28 day cycle.~Patients will receive 4 week cycles of study therapy for a maximum of 24 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm B: Paclitaxel
Description: Intravenous (i.v.) 1 hour infusions of Paclitaxel 90 mg/m\^2 on days 1, 8, 15 of each 28 day cycle.~Patients will receive 4 week cycles of study therapy for a maximum of 24 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent.
Study: NCT03052556

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pap smear test and HPV test
Description: Included women will attend a consultation with a gynaecologist. Pap smear test with HPV test will be performed. Samples collected by cervical scrape with a brush, will be prepared for liquid-based cytology. A sample of the sample will be used for research on HPV (Multiplex DNA PCR).~This method allows detection of 35 different HPV genotypes: high risk (HPV-16, -18, -26, -31, -33, -35, -39, -45, -51, -52, 53, -56, -58, -59, -66, -68, -70, -73, -82, and -85); and low risk (HPV-6, -11, -40, -42, -43, -44, -54, -61, -62, -71, -72, -81, -83, -84, and -89).~Patients with an initial abnormal pap smear or a positive HPV test will be monitored:~* In case of an abnormal smear and / or positive HPV test, pap smear and HPV testing will be renewed every 6 months during the study period~* In case of an abnormal smear:~ASC-US: the attitude will depend on the result of the HPV test ASC-H, LSIL, HSIL, AGUS, AGC, AIS, carcinoma: a colposcopy will be performed
Study: NCT01051401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: Given PO
Study: NCT03560531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c5
Description: ZN-c5 is a study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c5
Description: ZN-c5 is a study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib (IBRANCE®) is an approved drug
Study: NCT00606476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bapineuzumab (AAB-001)
Description: IV q13w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bapineuzumab (AAB-001)
Description: IV q13w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bapineuzumab (AAB-001)
Description: IV q13w
Study: NCT03498742

Intervention type: OTHER
Intervention: NO Intervention
Description: Routine clinical data; asthma control test and spirometry

Intervention type: OTHER
Intervention: NO Intervention
Description: Routine clinical data; asthma control test and spirometry
Study: NCT04628676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Description: Tranexamic acid is added to the irrigation fluid used in arthroscopic shoulder surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Epinephrine is added to the irrigation fluid used in arthroscopic shoulder surgery.
Study: NCT02054286

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: THV01-1
Description: Intramuscular injection of THV01-1 (week 0)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: THV01-2
Description: Intramuscular injection of THV01-2 (week 8)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: THV01-2
Description: Intramuscular injection of THV01-2 (week 8)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: THV01-2
Description: Intramuscular injection of THV01-2 (week 8)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular injection of placebo matching THV01-1 and THV01-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular injection of placebo matching THV01-1 and THV01-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular injection of placebo matching THV01-1 and THV01-2
Study: NCT03385291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: music,name,and noise sound
Description: A 5-minute baseline silence was followed by the presentation of three contrasting auditory stimuli(music,name,and noise), with a 2-minute washout silence separating each stimulus
Study: NCT02757326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opaganib
Description: Opaganib, \[3-(4-chlorophenyl)-adamantane-1-carboxylic acid (N-(Pyridin-4-ylmethyl)pyridine-4-carboxamide) amide, hydrochloride salt\] is an orally available inhibitor of the enzyme SK2.
Study: NCT01794455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: 50mg - 200mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: 4mg - 32mg daily
Study: NCT06579235

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics
Description: All samples of cases (with LNB) and controls (without LNB) will undergo proteomic analyses.

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics
Description: All samples of cases (with LNB) and controls (without LNB) will undergo proteomic analyses.
Study: NCT03396445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boserolimab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boserolimab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boserolimab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boserolimab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV infusion
Study: NCT03854734

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Event
Description: Formative focus group data was used to design an educational community event to improve information share and vaccine education/knowledge.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Material
Description: Formative focus group data was used to design educational messaging to be electronically distributed to intervention participants
Study: NCT03644082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Luminosity Trial Memory Match
Description: Working memory task that has users indicate whether the current symbol matches the one presented 2 symbols previously. As the user makes correct responses, the previous symbols reduce in contrast and fade int the background, ultimately disappearing, forcing the user to rely entirely on working memory to achieve success
Study: NCT01051401

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Correlative study

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: survey administration
Description: Correlative study
Study: NCT00929279

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bolus+infusion
Description: Abciximab bolus of 0.25mg /Kg, followed by a 12-h infusion 0.125 microg/Kg/min (to a maximum of 10 µg/min) and immediate clopidogrel at 300 mg loading regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abciximab bolus only regimen
Description: Abciximab bolus of 0.25mg /Kg followed by placebo infusion and immediate clopidogrel at 600 mg loading dose
Study: NCT04573894

Intervention type: DIAGNOSTIC_TEST
Intervention: Procalcitonin dosage
Description: Plasma PCT levels measured by automated enzyme immunoassay (Kryptor).
Study: NCT01632397

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-based counseling
Description: Cognitive Behavior Therapy for PrEP adherence

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education and supportive counseling
Description: Time matched general supportive therapy of the type commonly available from community therapists.
Study: NCT01404676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Add Vildagliptin
Description: Adding Vildagliptin 50 mg bid to patients with type 2 diabetes mellitus being treated with metformin 500-1000mg bid per day who had hemoglobin A1c of 7.0-10.0%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Add Glimepiride
Description: Adding Glimepiride 2mg to patients with type 2 diabetes mellitus being treated with metformin 500-1000mg bid per day who had hemoglobin A1c of 7.0-10.0%
Study: NCT02208804

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Holmium-166-poly (L-lactic acid) microspheres

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holmium-166-poly (L-lactic acid) microspheres
Study: NCT03231488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Description: A 10 minute mindfulness of breath exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention (unfocused attention)
Description: A 10 minute unfocused attention intervention - participants are asked to let their mind wander on anything that comes to mind.
Study: NCT02646605

Intervention type: OTHER
Intervention: depression screening
Description: Patient Health Questionnaire

Intervention type: OTHER
Intervention: depression screening
Description: Patient Health Questionnaire
Study: NCT01051401

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: management of therapy complications
Study: NCT01217320

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine
Description: 5g/d throughout 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo (dextrose)
Description: 5g/d throughout 12 weeks
Study: NCT03814434

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-Surgical treatment
Description: Implant and teeth surfaces decontamination through scaling and planning, Curettage, profilaxys and Oral Hygiene orientation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-Surgical treatment
Description: Implant and teeth surfaces decontamination through scaling and planning, Curettage, profilaxys and Oral Hygiene orientation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-Surgical treatment
Description: Implant and teeth surfaces decontamination through scaling and planning, Curettage, profilaxys and Oral Hygiene orientation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-Surgical treatment
Description: Implant and teeth surfaces decontamination through scaling and planning, Curettage, profilaxys and Oral Hygiene orientation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Treatment
Description: Anaesthesia, Incision, curettage, Treatment of the contaminated implant surface, Irrigation with saline, Guided Bone Regeneration and suture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Treatment
Description: Anaesthesia, Incision, curettage, Treatment of the contaminated implant surface, Irrigation with saline, Guided Bone Regeneration and suture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Treatment
Description: Anaesthesia, Incision, curettage, Treatment of the contaminated implant surface, Irrigation with saline, Guided Bone Regeneration and suture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Treatment
Description: Anaesthesia, Incision, curettage, Treatment of the contaminated implant surface, Irrigation with saline, Guided Bone Regeneration and suture
Study: NCT00277394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: innohep®
Description: 175 anti-Xa IU/kg administered subcutaneously (SC) once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Heparin 50 IU /kg followed by a total dose of 400 to 600 IU/kg/day divided into two SC injections daily.
Study: NCT03481426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Workplace intervention
Description: The study contains normal services of occupational health. Both intervention groups are based on voluntary will, and the normal care and services are guaranteed. In the intervention group new working method which improve co-operation between occupational health services and workplaces.
Study: NCT03150784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EPIC Club
Description: Weekly exercise gym sessions. Participants will start with a warm-up of 20-25 mins cardiovascular training either doing cycling, treadmill running or cross-training. The remainder of the session consists of strength/resistance and weight-training involving leg press, leg extensor, pull downs, kettle bells, dumbbells. In addition to the above, a novel rhythmical stepping task will be performed over 10 mins.

Intervention type: OTHER
Group type: OTHER
Intervention: EPIC Club
Description: Weekly exercise gym sessions. Participants will start with a warm-up of 20-25 mins cardiovascular training either doing cycling, treadmill running or cross-training. The remainder of the session consists of strength/resistance and weight-training involving leg press, leg extensor, pull downs, kettle bells, dumbbells. In addition to the above, a novel rhythmical stepping task will be performed over 10 mins.
Study: NCT04081272

Intervention type: DRUG
Intervention: Sodium Chromate Cr51
Description: Sodium Chromate Cr 51 will be used to perform a red blood cell recovered study 24 hours post-transfusion.

Intervention type: DRUG
Intervention: Sodium Chromate Cr51
Description: Sodium Chromate Cr 51 will be used to perform a red blood cell recovered study 24 hours post-transfusion.
Study: NCT00812903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Training exercises chosen with background in knowledge of intelligent training
Study: NCT02587546

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laryngeal carcinoma
Description: treatment of laryngeal carcinoma using thulium contact laser

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral vocal cord paralysis
Description: treatment of bilateral vocal cord paralysis using thulium contact laser

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subglottic stenosis
Description: treatment of subglottic stenosis using thulium contact laser
Study: NCT03087526

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Non invasive prenatal diagnosis
Description: Search for the familial mutation on isolated circulating fetal trophoblastic cells from maternal blood
Study: NCT00820404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI-489

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03731260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: Avapritinib tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: Avapritinib tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: Avapritinib tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: Avapritinib tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: Avapritinib tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT01731067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cocktail probe drugs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cocktail probe drugs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cocktail probe drugs
Study: NCT00369486

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Focal laser photocoagulation
Description: Focal laser photocoagulation (modified Early Treatment Diabetic Retinopathy Study technique)
Study: NCT01731067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocktail probe drugs
Study: NCT00547950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: :Deng Zhan Sheng Mai Capsule
Description: capsule，0.18g，2＃，po，Bid\*1year.
Study: NCT03166111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine gel
Description: syringe filled with 5 ml gel to be self-administered vaginal 10 minutes prior to insertion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: syringe filled with 5 ml gel to be self-administered vaginal 10 minutes prior to insertion
Study: NCT05040906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H02+CHOP
Description: Drug:H02 375 mg/m2,administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug : Cyclophosphamide 750 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug:Doxorubicin 50 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine 1.4mg mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituxan +CHOP
Description: Drug: Rituxan 375 mg/m2,administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug : Cyclophosphamide 750 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Doxorubicin 50 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug : Vincristine 1.4mg mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle.
Study: NCT01124877

Intervention type: DRUG
Group type: OTHER
Intervention: ziprasidone oral capsules
Description: Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength will be provided. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 40mg twice a day (BID) to a maximum dose range of 80 mg BID. For subjects weighing \<45 kg, the doses will range from 20 mg BID to 40 mg BID.
Study: NCT00065806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Participants weighing more 50 kg will receive 10 mg of atorvastatin po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo atorvastatin
Description: Participants weighing more 50 kg will receive 10 mg of placebo po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.
Study: NCT00440310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talaporfin sodium
Description: LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous placement of device in liver metastases
Description: Light Source placement will be conducted under placement imaging using ultrasound or CT guidance. No more than four Light Sources will be used at a single treatment session. The Light Sources may be used in a single lesion or in multiple lesions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interstitial light emitting diodes
Description: 200 J/cm per Light Source at 20 mW/cm light energy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX4 regimen
Description: Standard care chemotherapy regimen consisting of leucovorin, 5-FU and oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX4 regimen
Description: Standard care chemotherapy regimen consisting of leucovorin, 5-FU and oxaliplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI regimen
Description: Standard care chemotherapy regimen consisting of leucovorin, 5-FU and irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI regimen
Description: Standard care chemotherapy regimen consisting of leucovorin, 5-FU and irinotecan
Study: NCT01307293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Description: 6 or 12 sessions of cognitive behavior therapy.